Mode
Text Size
Log in / Sign up
N/A N=29 Randomized Single-blind Treatment

Sleep Disordered Breathing in Gulf War Illness and the Effect of Nasal CPAP Treatment

Apnea, Sleep · Chronic Fatigue Syndrome

Enrolled (actual)
29
Serious AEs
0.0%
Results posted
Dec 2014
Primary outcome: Primary: Change of Fatigue Symptom — 2.1; 0.2 units on a scale — p=0.0002

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Nasal CPAP treatment during sleep (Other)
Age
Adult · 32+ yrs
Sex
Male
Sponsor
US Department of Veterans Affairs
Primary completion
Oct 2008

Outcome Measures

OutcomeResultp-value
PRIMARY
Change of Fatigue Symptom
2.1; 0.2 0.0002 sig
PRIMARY
The Prevalence of Inspiratory Flow Limitation (IFL) During Sleep in GWS.
96; 36 0.0001 sig
SECONDARY
Change of Pain Complaint
2.0; 0.4 0.0008 sig
SECONDARY
Change of Cognitive Dysfunction
2.0; 0.4 0.004 sig

Summary

The purpose of this study is to determine any sleep disordered breathing in veterans with Gulf War Syndrome (GWS) and compare it to healthy normal asymptomatic Gulf War veterans. This study will also determine the effect of treatment with continuous positive airway pressure on veterans with Gulf War Syndrome. 1. The investigators hypothesize that sleep complaints (insomnia, un-refreshing sleep and daytime fatigue) among GWS patients are related to increased sleep fragmentation secondary to the presence of sleep disordered breathing in GWS patients. 2. The investigators hypothesize that increased collapsibility of the upper airway during sleep with the development of inspiratory flow limitation (IFL) and sleep disordered breathing causes the increased sleep fragmentation in GWS patients. 3. The investigators hypothesize that correction of IFL and sleep disordered breathing in GWS patients will result in an improvement of their sleep quality resulting in an improvement of their sleep complaints and other functional symptoms.

Eligibility Criteria

Inclusion Criteria

  • First Gulf War veterans with and without the syndrome
  • Males
  • Between 32 and 52 years of age
  • No history of current alcoholism nor opiate use
  • No history of current active depression nor post-traumatic stress disorder (PTSD)

Exclusion Criteria

  • Females
  • History of active alcoholism or opiate drug use
  • History of active depression and PTSD
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00252629). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search